Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Revenue of Mirum Pharmaceuticals, Inc. (MIRM)
Revenue in 2023 (TTM): $186.37 M
According to Mirum Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $186.37 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Mirum Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $186.37 M | $139.01 M | $-98,325,000 | $-162,424,000 | $-163,415,000 |
| 2022 | $77.06 M | $64.69 M | $-126,998,000 | $-142,071,000 | $-135,665,000 |
| 2021 | $19.14 M | $17.24 M | $-64,654,000 | $-83,951,000 | $-83,988,000 |
| 2020 | $ | $-623,000 | $-102,929,000 | $-103,264,000 | $-103,270,000 |
| 2019 | $ | $-324,000 | $-54,743,000 | $-52,532,000 | $-52,553,000 |
| 2018 | $ | $ | $-2,916,000 | $-17,348,000 | $-17,348,000 |